ARWR Stock Price Today (July 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-07-17
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $74.30, up 4.10% today (as of July 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $89.08 (19.9% upside).
- Volatility remains elevated (46.71% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-86.40% YoY) alongside significant competitive pressures.
ARWR Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $11.07B
P/E Ratio
Forward P/E: -18.80
Revenue Growth
Year over Year
Analyst Target
+19.9% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 39.69)
- Fundamentals say: Challenging (declining revenue trends)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.38B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $14.30 and $84.55—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 46.71% annualized volatility and β=1.76, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Arrowhead gains EU authorisation for Redemplo in evolving FCS market
EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Apple, Bloom Energy, Circle Internet Group, First Solar, Halliburton, IBM, Intuit, Newmont, SK hynix, and More
Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and Mizuho made some bold calls you may not see coming.
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.
The Long Climb Back For Ionis Stock
A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval
Goldman Sachs upped its price target on Ionis to $75 and maintained a ‘Neutral’ rating on the shares.
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus
Arrowhead Pharmaceuticals presented new clinical data on plozasiran in patients with moderate to severe renal or hepatic impairment at a major scientific congress. The data focused on efficacy and safety outcomes in these higher risk groups. A separate case report highlighted long term triglyceride reduction with plozasiran use during pregnancy. For investors watching Arrowhead Pharmaceuticals (NasdaqGS:ARWR), these updates come with the stock at $74.95 and 1 year gains of 387.6%. The move...
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had […]
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $74.30. The RSI (14-day) is at 39.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $89.08 implies 19.9% upside from current levels. Volatility is high at 46.7% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is -32.73, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -18.80. Price-to-Book is 17.01. Price-to-Sales is 16.83. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ARWR, the consensus price target is $89.08. This represents a 19.9% upside from the current price of $74.30. The range spans from a low target of $46.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. High volatility (46.7% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 231.05) which could pressure margins in a rising rate environment. 3. Declining revenue (-86.4% YoY), indicating potential business headwinds. 4. Elevated short interest (11.6% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $1.38B. The debt-to-equity ratio is 231.05, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 6.23, indicating strong short-term liquidity. The quick ratio is 6.09. The company holds $1.78B in cash and equivalents. Free cash flow is negative at $-46,121,248, which could limit the company's ability to manage debt obligations.